BIOCARTIS NV

Their core work

Biocartis is a Belgian diagnostics technology company focused on molecular diagnostics and lab-on-a-chip platforms. Their H2020 participation shows two distinct industrial contributions: first as an industry partner in a research training network on new infectious disease diagnostics, then as a commercial actor in an innovation project developing additive manufacturing techniques for 3D microfluidic MEMS devices. Their core competence sits at the intersection of clinical diagnostics and microfluidic engineering — they bring real-world device development experience into research consortia. With only €132K in direct EC funding across both projects, they participate as specialist industrial contributors rather than as grant recipients, which is typical for companies providing testbeds, platforms, or industry validation.

What they specialise in

How they've shifted over time

Their first H2020 engagement (ND4ID, 2016) placed them in a training and research context for infectious disease diagnostics — with no technical keywords recorded, suggesting a supporting or validation role rather than a technical lead. By 2018, their second project (M3DLoC) shows a clear pivot toward the manufacturing layer: lab-on-a-chip fabrication, sensor integration, and 3D printing pilot lines. The shift is from clinical application (what diagnostics test) to manufacturing method (how diagnostic chips are built).

Biocartis appears to be moving from end-user diagnostics applications toward upstream manufacturing technology for microfluidic devices, making them a relevant partner for projects combining advanced fabrication with biomedical sensing.

How they like to work

Biocartis has never coordinated a project — both participations are as consortium member, which is consistent with an industrial SME joining research-led projects to provide industry validation or access to commercial platforms. Their consortia are unusually large (40 unique partners across 14 countries from just 2 projects), indicating they have joined broad pan-European networks rather than tight bilateral collaborations. This suggests they are sought as an industry reference point within large research consortia, not as a team that builds its own project structures.

Despite only 2 projects, Biocartis has touched 40 unique consortium partners across 14 countries — a wide network footprint that reflects participation in large, multi-partner consortia. No geographic cluster is visible from the data, suggesting their network is broadly European rather than regionally concentrated.

What sets them apart

Biocartis occupies a rare position as a commercial diagnostics SME that bridges clinical application and chip-level manufacturing R&D. Most academic lab-on-chip groups lack direct commercial device experience; Biocartis brings that to a consortium as an industry validation partner. For a project needing an industrial counterpart with real product development history in molecular diagnostics, this company is a credible and uncommon choice.

Highlights from their portfolio

• M3DLoC
  An Innovation Action targeting 3D additive manufacturing of microfluidic MEMS — this is applied, near-market work with a pilot line component, making it the more industrially significant of the two participations.
• ND4ID
  A Marie Skłodowska-Curie training network for infectious disease diagnostics — notable because Biocartis joined as an industry host, providing early-career researchers access to a commercial diagnostics environment.